CYP2A6: A human coumarin 7-hydroxylase

Toxicology

Volumn 144, Issue 1-3, 2000, Pages 139-147

  Pelkonen, Olavi ^a   Rautio, Arja ^a   Raunio, Hannu ^a   Pasanen, Markku ^b  

^a UNIVERSITY OF OULU   (Finland)

^b NATIONAL AGENCY FOR MEDICINES   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 DIMETHYL 2 (3 PYRIDYL) 4 THIAZOLIDINONE; AFLATOXIN; ALCOHOL; CARCINOGEN; CLOTRIMAZOLE; COTININE; COUMARIN; COUMARIN 7 HYDROXYLASE; CYTOCHROME P 450 CYP2A6; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; ELLIPTICINE; FLAVONOID; GRISEOFULVIN; HALOTHANE; KETOCONAZOLE; LEAD; MESSENGER RNA; METHOXSALEN; METHOXYFLURANE; NICOTINE; NITROSAMINE; PHENOBARBITAL; PILOCARPINE; RIFAMPICIN; UNCLASSIFIED DRUG;

DRUG HYDROXYLATION; DRUG OXIDATION; ENZYME SPECIFICITY; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; KIDNEY DISEASE; LIVER DISEASE; LIVER MICROSOME METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; XENOBIOTIC METABOLISM;

EID: 0034599544     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(99)00200-0     Document Type: Article

References (71)

1. Bourrie M., Meunier V., Berger Y., Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996;321-332.
2. Camus A.-M., Geneste O., Honkakoski P., Bereziat J.-C., Henderson C.J., Wolf C.R., Bartsch H., Lang M.A. High variability of nitrosamine metabolism among individuals: role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodietylamine in mice and humans. Mol. Carcinog. 7:1993;268-275.
3. Cashman J.R., Park S.B., Yang Z.-C., Wrighton S.A., Jacob P., Benowitz N.L. Metabolism of nicotine by human liver microsomes: steroselective formation of trans-nicotine N′-oxide. Chem. Res. Toxicol. 5:1992;639-646.
4. Chang T.K.H., Waxman D.J. The CYP2A subfamily. Ioannides C. Cytochromes P450. Metabolic and Toxicological Aspects. 1996;99-134 CRC Press, Boca Raton, FL.
5. Cholerton S., Boustead C., Taber H., Arpanahi A., Idle J.R. CYP2D6 genotypes in cigarette smokers and non-tobacco users. Pharmacogenetics. 6:1996;261-263.
6. Cholerton S., Idle M.E., Vas A., Gonzalez F.J., Idle J.R. Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. J. Chromatogr. 575:1992;325-330.
7. 3H-pentyl]methyl-n-amylnitrosamine by rat esophageal and liver microsomes and by rat and human cytochrome P450 isoforms. Cancer Res. 59:1999;91-98.
8. Crespi C.L., Penman B.W., Leakey J.A.E., Arlotto M.P., Stark A., Parkinson A., Turner T., Steimel D.T., Rudo K., Davies R.L., Langenbach R. Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis. 11:1990;1293-1300.
9. Dalet-Beluche I., Boulenc X., Fabre G., Maurel P., Bonfils C. Purification of two cytochrome P450 isozymes related to CYP2A and CYP3A gene families from monkey (baboon, Papio papio) liver microsomes: cross reactivity with human forms. Eur. J. Biochem. 204:1992;641-648.
10. Ding X., Spink D.C., Bhama J.K., Sheng J.J., Vaz A.D.N., Coon M.J. Metabolic activation of 2,6-dichlorobenzonitrile, an olfactory-specific toxicant, by rat, rabbit and human cytochromes P450. Mol. Pharmacol. 49:1996;1113-1121.
11. Draper A.J., Madan A., Parkinson A. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch. Biochem. Biophys. 341:1997;47-61.
12. Duescher R.J., Elfarra A.A. Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochromes P450 2A6 and 2E1. Arch. Biochem. Biophys. 311:1994;342-349.
13. Fernandez-Salguero P., Gonzalez F.J. The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics. 5:1995;S123-S128.
14. Fernandez-Salguero P., Hoffman S.M.G., Cholerton S., Mohrenweiser H., Raunio H., Rautio A., Pelkonen O., Huang J., Evans W.E., Idle J.R., Gonzalez F.J. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet. 57:1995;651-660.
15. Gullstén H., Agundez J.A.G., Benitez J., Läärä E., Ladero J.M., Diaz-Rubio M., Fernandez-Salguero P., Gonzalez F., Rautio A., Pelkonen O., Raunio H. CYP2A6 gene polymorphism and risk of liver cancer and cirrhosis. Pharmacogenetics. 7:1997;247-250.
16. Hakkola J., Pasanen M., Purkunen R., Saarikoski S., Pelkonen O., Mäenpää J., Rane A., Raunio H. Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. Biochem. Pharmacol. 48:1994;59-64.
17. Hakkola J., Tanaka E., Pelkonen O. Developmental expression of cytochrome P450 enzymes in the human liver. Pharmacol. Toxicol. 82:1998;209-217.
18. Hoffman S.M.G., Fernandez-Salguero P., Gonzalez F.J., Mohrenweiser H.W. Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19. J. Mol. Evolut. 41:1995;894-900.
19. Iscan M., Rostami H., Guray T., Pelkonen O., Rautio A. A study on the interindividual variability of coumarin 7-hydroxylation in a Turkish population. Eur. J. Clin. Pharmacol. 47:1994;315-318.
20. Kharasch E.D., Hankins D.C., Thummel K.E. Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology. 82:1995;689-699.
21. Khojasteh-Bakht S.C., Koenigs L.L., Peter R.M., Trager W.F., Nelson S.D. (R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6. Drug Metab. Dispos. 26:1998;701-704.
22. Kimonen T., Juvonen R.O., Alhava E., Pasanen M. The inhibition of CYP enzymes in mouse and human liver by pilocarpine. Br. J. Pharmacol. 114:1995;832-836.
23. Kimonen T., Pasanen M., Gynther J., Poso A., Järvinen T., Alhava E., Juvonen R.O. Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP2A5 and human CYP2A6. Br. J. Pharmacol. 116:1995;2625-2630.
24. Kirby G.M., Batist G., Alpert L., Lamoureux E., Cameron R.G., Alaoui-Jamali M.A. Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis. Toxicol. Pathol. 24:1996;458-467.
25. Koenigs L.L., Peter R.M., Thompson S.J., Rettie A.E., Trager W.F. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab. Disp. 25:1997;1407-1415.
26. Koskela S., Hakkola J., Hukkanen J., Pelkonen O., Sorri M., Saranen A., Anttila S., Fernandez-Salguero P., Gonzalez F.J., Raunio H. Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem. Pharmacol. 57:1999;1407-1413.
27. Mäenpää J., Juvonen R., Raunio H., Rautio A., Pelkonen O. Methoxsalen and coumarin interactions in man and mouse. Biochem. Pharmacol. 48:1994;1363-1369.
28. Maurice M., Emiliani S., Dalet-Beluche I., Derancourt J., Lange R. Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes. Eur. J. Biochem. 200:1991;511-517.
29. Merkel U., Sigusch H., Hoffmann A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur. J. Clin. Pharmacol. 46:1994;175-177.
30. Miles J.S., McLaren A.W., Forrester L.M., Glancey M.J., Lang M.A., Wolf C.R. Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem. J. 267:1990;365-371.
31. Mustajoki P., Mustajoki S., Rautio A., Arvela P., Pelkonen O. Effects of heme arginate on cytochrome P450-mediated metabolism of drugs in patients with variegate porphyria and healthy men. Clin. Pharmacol. Ther. 56:1994;9-13.
32. Nakajima M., Yamamoto T., Nunoya K.-I., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki T., Kuroiwa Y. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996a;1010-1015.
33. Nakajima M., Yamamoto T., Nunoya K.-I., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kuroiwa Y. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos. 24:1996b;1212-1217.
34. Nunoya K.-I., Yokoi T., Kimura K., Kodama T., Funayama M., Inoue K., Nagashima K., Funae Y., Shimada N., Green C., Kamataki T. (+)-Cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996;768-774.
35. Nunoya K.-I., Yokoi T., Kimura K., Inoue K., Kodama T., Funayama M., Nagashima K., Funae Y., Green C., Kinoshita M., Kamataki T. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics. 8:1998;239-249.
36. Oscarson M., Gullstén H., Rautio A., Bernal M.L., Sinues B., Dahl M.-L., Stengård J.H., Pelkonen O., Raunio H., Ingelman-Sundberg M. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett. 438:1998;201-205.
37. Oscarson M., McLellan R.A., Gullstén H., Yue Q.-Y., Lang M.A., Bernal M.L., Sinues B., Hirvonen A., Raunio H., Pelkonen O., Ingelman-Sundberg M. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 448:1999;105-110.
38. Palmer C.N.A., Coates P.J., Davies S.E., Shephard E.A., Phillips I.R. Localization of cytochrome P-450 gene expression in normal and diseased human liver by in situ hybridization of wax-embedded archival material. Hepatology. 16:1992;682-687.
39. Pasanen M., Rannala Z., Tooming A., Sotaniemi E.A., Pelkonen O., Rautio A. Hepatitis A impairs the function of human hepatic CYP2A6 in vivo. Toxicology. 123:1997;177-184.
40. Pearce R., Greenway D., Parkinson A. Species differences and interindividual variation in liver microsomal cytochrome P4502A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch. Biochem. Biophys. 298:1992;211-225.
41. Pelkonen O., Raunio H. Individual expression of carcinogen-metabolizing enzymes: cytochrome P4502A. J. Occup. Environ. Med. 37:1995;19-24.
42. Pelkonen O., Sotaniemi E.A., Ahokas J.T. Coumarin 7-hydroxylase activity in human liver microsomes: properties of the enzyme and interspecies comparisons. Br. J. Clin. Pharmacol. 19:1985;59-66.
43. Pelkonen O., Raunio H., Rautio A., Mäenpää J., Lang M.A. Coumarin 7-hydroxylase: characteristics and regulation in mouse and man. J. Irish Coll. Phys. Surg. 22:1993;24-28.
44. Pelkonen O., Rautio A., Raunio H. Specificity and applicability of probes for drug metabolizing enzymes. Alvan G., Balant L.P., Bechtel P.R., Boobis A.R., Gram L.F., Paintaud G., Pithan K. European Cooperation in the Field of Scientific and Technical Research-COST B1 Conference on the Variability and Specificity in Drug Metabolism. 1995;147-158 European Commission, Luxenbourg.
45. Pelkonen O., Raunio H., Pasanen M., Rautio A., Lang M.A. The metabolism of coumarin. O'Kennedy R., Thornes R.D. Coumarins Biology, Applications and Mode of Action. 1997;67-92 Wiley, Chichester.
46. Pianezza M.L., Sellers E.M., Tyndale R.F. Nicotine metabolism defect reduces smoking. Nature. 393:1998;750.
47. Rauma A.-L., Rautio A., Pasanen M., Pelkonen O., Törrönen R., Mykkänen H. Coumarin 7-hydroxylation in long-term adherents of a strict uncooked vegan diet. Eur. J. Clin. Pharmacol. 50:1996;133-137.
48. Raunio H., Syngelmä T., Pasanen M., Juvonen R., Honkakoski P., Kairaluoma M.A., Sotaniemi E.A., Lang M., Pelkonen O. Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat and mouse. Biochem. Pharmacol. 37:1988;3889-3895.
49. Raunio H., Juvonen R., Pasanen M., Pelkonen O., Pääkkö P., Soini Y. Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma. Hepatology. 27:1998;427-432.
50. Raunio H., Rautio A., Pelkonen O. The CYP2A subfamily: function, expression and genetic polymorphism. Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J, Boffetta P Metabolic Polymorphisms and Susceptibility to Cancer, IARC Scientific Publications No 148, International Agency for Research on Cancer, Lyon. 1999;197-207.
51. Rautio A., Kraul H., Kojo A., Salmela E., Pelkonen O. Interindividual variability of coumarin 7-hydroxylation in healthy individuals. Pharmacogenetics. 2:1992;227-233.
52. Rautio A., Salmela E., Arvela P., Pelkonen O., Sotaniemi E.A. Assessment of CYP2A6 and CYP3A4 activities in vivo in different diseases in man. Lechner M.C. Cytochrome P450: Biochemistry, Biophysics and Molecular Biology. 1994;519-521 John Libbey Eurotext, Paris.
53. Reigh G., McMahon H., Ishizaki M., Ohara T., Shimane K., Esumi Y., Green C., Tyson C., Ninomiya S. Cytochrome P450 species involved in the metabolism of quinoline. Carcinogenesis. 17:1996;1989-1996.
54. Rodrigues A.D. Use of in vitro human metabolism studies in drug development: an industrial perspective. Biochem. Pharmacol. 48:1994;2147-2156.
55. Rodrigues A.D. Integrated cytochrome P450 reaction phenotyping. Biochem. Pharmacol. 57:1999;465-480.
56. Sadeque A.J.M., Fisher M.B., Korzekwa K.R., Gonzalez F.J., Rettie A.E. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J. Pharmacol. Exp. Ther. 283:1997;698-703.
57. Salonpää P., Hakkola J., Pasanen M., Pelkonen O., Vähäkangas K., Battula N., Nouso K., Raunio H. Retrovirus-mediated stable expression of human CYP2A6 in mammalian cells. Eur. J. Pharmacol. Environ. Toxicol. Pharmacol. 248:1993;95-102.
58. Satarug S., Lang M.A., Yongvanit P., Sithithaworn P., Mairiang E., Mairiang P., Pelkonen P., Bartsch H., Haswell-Elkins M.R. Induction of cytochrome P4502A6 expression in humans by the carcinogenic parasite infection, Opisthorchiasis viverrini. Cancer Epidemiol. Biomark. Prev. 5:1996;795-800.
59. Shimada T., Yamazaki H., Guengerich F.P. Ethnic-related differences in coumarin 7-hydroxylation activity catalyzed by cytochrome P2402A6 in liver microsomes of Japanese and Caucasians populations. Xenobiotica. 26:1996;395-403.
60. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:1994;414-423.
61. Sotaniemi E.A., Rautio A., Bäckström M., Arvela P., Pelkonen O. Hepatic cytochrome P450 isozyme (CYP2A6 and CYP3A4) activities and fibrotic process in liver. Br. J. Clin. Pharmacol. 39:1995;71-76.
62. Spracklin D.K., Thummel K.E., Kharasch E.D. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P4502A6 and 3A4. Drug Metab. Dispos. 24:1996;976-983.
63. Thornton-Manning J., Appleton M.L., Gonzalez F.J., Yost G.S. Metabolism of 3-methylindole by vaccinia-expressed P450 enzymes: correlation of 3-methyleneindolenine formation and protein-binding. J. Pharmacol. Exp. Ther. 276:1996;21-29.
64. Tiano H.F., Hosokawa M., Clulada P.C., Smith P.B., Wang R., Gonzalez F.J., Crespi C.L., Langenbach R. Retroviral mediated expression of human cytochrome P4502A6 in C3H/10T1/2 cells confers transformability by 4-(methylnitrosamino)-1-(3-pyridyl)1-butanone (NNK). Carcinogenesis. 14:1993;1421-1427.
65. Torchin C.D., McNeilly P.J., Kapetanovic I.M., Strong J.M., Kupferberg H.J. Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes. Drug Metab. Dispos. 24:1996;1002-1008.
66. Waxman D.J., Lapenson D.P., Aoyama T., Gelboin H.V., Gonzalez F.J., Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch. Biochem. Biophys. 290:1991;160-166.
67. Yamano S., Tatsuno J., Gonzalez F.J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 29:1990;1322-1329.
68. Yamazaki H., Inui Y., Yun C.-H., Guengerich F.P., Shimada T. Cytochrome P4502E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis. 13:1992;1789-1794.
69. Yun C.-H., Shimada T., Guengerich F.P. Purification and characterization of human liver microsomal cytochrome P4502A6. Mol. Pharmacol. 40:1991;679-685.
70. Yun C.-H., Shimada T., Guengerich F.P. Contributions of human liver cytochrome P450 enzymes to the N-oxidation of 4,4′-methylene-bis(2-chloroaniline). Carcinogenesis. 13:1992;217-222.
71. Zhuo X., Gu J., Zhang Q.-Y., Spink D.C., Kaminsky L.S., Ding X. Biotransformation of coumarin by rodent and human cytochromes P450: metabolic basis of tissue-selective toxicity in olfactory mucosa of rats and mice. J. Pharmacol. Exp. Ther. 288:1999;463-471.